D3 antagonist
D3 dopamine receptor antagonist
- Dampens incentive salience → may reduce impulsivity and craving
- Minimal EPS because motor control is primarily D2-mediated
- Does not contribute to EPS, tranquilization or sedation
- Dampens incentive salience — reduced impulsivity and craving
Drugs with this mechanism (22)
- Amisulpride — Benzamide antipsychotic (not US-marketed); low-dose antidepressant effect.
- Asenapine — Sublingual/transdermal atypical; oral tablets are ineffective if swallowed.
- Asenapine transdermal — Once-daily asenapine patch - the only transdermal antipsychotic.
- Chlorpromazine — The first antipsychotic; low-potency, very sedating, with broad receptor blockade.
- Chlorpromazine injection — Injectable low-potency antipsychotic for agitation; also treats severe nausea and intractable hiccups.
- Haloperidol — Prototypical high-potency typical antipsychotic; potent D2 blocker, high EPS risk.
- Haloperidol decanoate LAI — First-generation D2-antagonist depot for schizophrenia maintenance; EPS burden is high.
- Haloperidol injection — Parenteral high-potency D2 antipsychotic for acute agitation; IV use magnifies QT concern.
- Iloperidone — Atypical requiring slow titration for orthostasis; QT prolongation.
- Paliperidone — Active metabolite of risperidone; extended-release oral and long-acting injectables.
- Paliperidone palmitate LAI — Long-acting paliperidone palmitate injection for schizophrenia-spectrum maintenance.
- Paliperidone palmitate LAI — Longest-interval paliperidone depot; requires prior stability on a shorter formulation.
- Paliperidone palmitate LAI — Long-acting paliperidone injection for schizophrenia and schizoaffective disorder.
- Paliperidone palmitate LAI — Extended-interval paliperidone LAI for schizophrenia; prior stabilization on a shorter formulation is required.
- Pimozide — High-potency typical reserved for Tourette; notable QT risk.
- Risperidone — Widely used atypical; dose-related EPS and the class's greatest prolactin burden.
- Risperidone LAI — Microsphere antipsychotic depot; delayed release requires oral overlap and relatively frequent injections.
- Risperidone LAI — Subcutaneous long-acting risperidone for schizophrenia; no oral supplementation after injection.
- Risperidone LAI — Long-acting risperidone depot for schizophrenia; formulated without a prolonged oral bridge.
- Risperidone LAI — Long-acting risperidone microsphere injection for schizophrenia and bipolar I maintenance.
- Risperidone LAI — Subcutaneous extended-release risperidone; no loading dose or oral overlap after initiation.
- Trifluoperazine — High-potency first-generation antipsychotic; low metabolic burden but high movement risk.
All mechanisms · Open D3 antagonist in the interactive console ↗